Spectral AI (NASDAQ:MDAI) vs. iRadimed (NASDAQ:IRMD) Head to Head Review

Spectral AI (NASDAQ:MDAI) and iRadimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Valuation and Earnings

This table compares Spectral AI and iRadimed”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$27.55 million	2.24	-$15.31 million	($0.69)	-3.35
iRadimed	$73.24 million	12.20	$19.23 million	$1.62	43.35

iRadimed has higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Spectral AI and iRadimed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	1	0	3.00
iRadimed	0	0	1	0	3.00

Spectral AI currently has a consensus price target of $3.50, indicating a potential upside of 51.52%. iRadimed has a consensus price target of $72.00, indicating a potential upside of 2.52%. Given Spectral AI’s higher probable upside, research analysts plainly believe Spectral AI is more favorable than iRadimed.

Institutional & Insider Ownership

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 30.7% of Spectral AI shares are owned by insiders. Comparatively, 36.8% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Spectral AI has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

Profitability

This table compares Spectral AI and iRadimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-51.97%	N/A	-8.69%
iRadimed	26.61%	23.30%	20.62%

Summary

iRadimed beats Spectral AI on 11 of the 12 factors compared between the two stocks.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.